Selected article for: "effective remain and recent study"
Author: Mohammed Abdul, Mubeen Khan; Snyder, Heather S.; Chunduru, Mythili; Lee, Susan M.K.; Satapathy, Sanjaya K.
Title: Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure
  • Cord-id: 0tepkjdl
  • Document date: 2020_8_11
    • ID: 0tepkjdl
    Snippet: PURPOSE OF REVIEW: Hepatitis C (HCV) is the most common cause of viral hepatitis in elderly individuals. This patient population previously experienced suboptimal outcomes with interferon-based regimens. Unfortunately, patients aged 65 years and older were underrepresented in phase 2 and 3 clinical trials with newer direct acting antiviral (DAA) therapies. Since the advent of second-generation DAA in 2013, numerous robust real-world experiences highlighting the efficacy and safety of DAA in the
    Document: PURPOSE OF REVIEW: Hepatitis C (HCV) is the most common cause of viral hepatitis in elderly individuals. This patient population previously experienced suboptimal outcomes with interferon-based regimens. Unfortunately, patients aged 65 years and older were underrepresented in phase 2 and 3 clinical trials with newer direct acting antiviral (DAA) therapies. Since the advent of second-generation DAA in 2013, numerous robust real-world experiences highlighting the efficacy and safety of DAA in the elderly have been published. This review article summarizes the cascade of care for hepatitis C from diagnosis to cure from an evidence-based perspective of the aging population. RECENT FINDING: In a large study from the Veterans Affairs Healthcare System, the overall sustained virologic response (SVR) of 15,884 patients treated with DAA regimens was 91.2%. These newer therapies remained highly effective in the subset of patients aged 65 years and older with SVR rates above 90%. A Spanish National Registry reported outcomes in patients ≥ 65 years old treated for HCV with oral DAA regimens over a 2-year period. The overall SVR was 94% in the study of 1252 subjects. SUMMARY: Current real-world data imply DAA treatment regimens remain highly effective and safe in elderly patients when compared to the general population.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and liver diseases: 1
    • absence presence and liver fibrosis: 1
    • active infection and acute phase: 1, 2, 3, 4, 5, 6, 7
    • active infection and administration time: 1, 2
    • active infection and liver disease: 1, 2, 3, 4, 5
    • active infection and liver disease severity: 1
    • active infection and liver diseases: 1
    • active infection and liver transplant: 1, 2
    • acute phase and administration time: 1, 2, 3
    • acute phase and liver disease: 1, 2, 3, 4, 5, 6
    • acute phase and liver disease severity: 1
    • acute phase and liver fibrosis: 1
    • acute phase and liver transplant: 1
    • administration time and liver disease: 1
    • administration time and liver transplant: 1, 2